摘要
目的:探讨胞质型磷脂酶A2(cPLA2)mRNA表达、白三烯C4(TLC4)在哮喘发病中的作用及其相互关系,以及砒石对哮喘的治疗作用。方法:建立小鼠卵蛋白哮喘模型,砒石灌胃给药,用逆转录聚合酶链反应方法检测肺组织中cPLA2mRNA表达;ELISA方法检测支气管肺泡灌洗液(BALF)中LTC4含量;微量滴定法测定BALF中PLA2活性。应用新航YP200型压力换能器及Medlab生物信号采集系统检测小鼠肺功能Pmax和T呼T总。结果:哮喘小鼠肺组织cPLA2基因表达水平、BALF中PLA2活性、LTC4水平均较对照组显著升高。0.625、1.25、2.50及5.00mg·kg-1剂量的砒石可下调哮喘小鼠cPLA2mRNA表达,抑制哮喘小鼠BALF中PLA2活性和降低LTC4水平,改善哮喘小鼠肺功能。结论:支气管肺组织中cPLA2基因表达上调、PLA2活性和LTC4水平增高在卵蛋白(OVA)致敏小鼠哮喘发病中起着重要作用。砒石可显著抑制哮喘小鼠肺组织中cPLA2基因的表达,降低哮喘小鼠PLA2活性和降低LTC4水平,改善哮喘小鼠肺功能,具有抗哮喘活性。
AIM: To study the effects of arsenolite on the leukotriene C_4 and the expression of cPLA_2 mRNA in ovalbumin challenged asthmatic mice. METHODS: 56 mice were randomly divided into 7 groups. Establishing the ovalbumin sensitized asthmatic model, RT-PCR was employed to detect the expression of cPLA_2 mRNA in the lung. The TLC_4 and PLA_2 in BALF were measured by ELISA.Expiration time/respiratory total time and expiration maximum pressure were detected. RESULTS: The expression of PLA_2 mRNA in the lung and the TLC_4, PLA_2 activity in BALF in asthmatic group were significantly higher than those in normal group. After therapy with dexamethasone and different dosage of arsenolite( 0.625, 1.25, 2.50 and 5.00 mg·kg -1),the expression of PLA_2 mRNA and the TLC_4, PLA_2 activity were significantly lower than those in asthmatic group. Expiration time/respiratory total time and expiration maximum pressure in asthmatic group were significantly increased compared with normal group. Expiration time/respiratory total time and expiration maximum pressure of groups treated with 4 doses arsenolite were significantly decreased compared with asthmatic group. CONCLUSION: PLA_2 mRNA expression increases in asthma group, and arsenolite can efficiently treat asthma. Its mechanism maybe partly relates to decreasing TLC_4 in airway and the inhibition of PLA_2 mRNA expression.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2005年第6期659-663,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
广东省中医药局课题(№100023)
